Importantly, blockade of PI3K or PDK1 activity elicited a marked inhibition of KRAS-dependent metaplasia and tumorigenesis, thus suggesting also that the KRAS→PI3K→PDK1 pathway may represent a potentially important target in pancreatic cancer therapy [118]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.